CORT: FDA Warning Hits Shares Again—What’s Next?

Overview of Recent FDA Setbacks and Share Impact

Corcept Therapeutics (NASDAQ: CORT) has experienced two sharp sell-offs in quick succession due to setbacks with its lead drug candidate. On December 31, 2025, the company announced that the U.S. Food and Drug Administration (FDA) declined to approve relacorilant – its cortisol-modulating drug for Cushing’s syndrome – after concluding it “could not arrive at a favorable benefit–risk assessment… without additional evidence of effectiveness” (www.spglobal.com). This surprise rejection sent Corcept’s stock tumbling by almost 50% that day (www.spglobal.com). Barely a month later, shares plunged another 16% on January 30, 2026, when a corrected FDA Complete Response Letter (CRL) revealed the agency had explicitly warned Corcept “on several occasions” not to file the relacorilant application (wtaq.com) (wtaq.com). In other words, management’s professed surprise at the rejection was undermined by FDA documentation that repeatedly cautioned of “significant review issues” well before submission (wtaq.com). These back-to-back regulatory blows have erased a large portion of Corcept’s market value, leaving investors asking: What comes next for CORT?

Company Profile and Product Portfolio

Corcept is a commercial-stage biotech focused on cortisol modulation therapies. Its sole marketed product, Korlym® (mifepristone), was approved in 2012 for endogenous Cushing’s syndrome (hypercortisolism) and has driven the company’s growth for over a decade (www.biospace.com). Korlym remains the cornerstone of Corcept’s revenues, which reached $675.0 million in 2024, up 40% from 2023 (ir.corcept.com). The company had pinned its next phase of growth on relacorilant, a selective cortisol receptor antagonist developed to treat patients with Cushing’s syndrome who have hypertension (www.investing.com). Relacorilant was expected to be a major new revenue driver beyond Korlym (www.spglobal.com), potentially allowing Corcept to defend its Cushing’s franchise as Korlym faces generic competition. The drug is also being studied in oncology indications, including platinum-resistant ovarian cancer and endometrial cancer (www.spglobal.com). However, the FDA’s refusal to approve relacorilant for Cushing’s has dented Corcept’s growth prospects considerably. Analyst projections for relacorilant’s sales were slashed after the rejection – near-term forecasts dropped by ~65% (to $140 million from $401 million previously), and peak sales expectations for 2028 were cut from about $1.1 billion to just $369 million (www.spglobal.com). In short, what was once seen as a potential blockbuster is now in limbo, forcing Corcept to regroup and re-strategize.

Dividend Policy and Shareholder Returns

Corcept does not pay a dividend, and has never issued any regular cash dividend to shareholders (www.macrotrends.net). The company’s policy has been to reinvest profits into R&D and to return capital via share repurchases rather than dividends. In fact, Corcept’s board authorized a $200 million stock buyback program in early 2024 (www.sec.gov). Throughout 2023–2024, the company utilized this program (and a prior tender offer) to repurchase a substantial amount of shares. By September 30, 2024, Corcept had about 104.8 million shares outstanding with an additional 32.4 million shares held in treasury from buybacks (www.sec.gov) (www.sec.gov). During 2024 alone, Corcept spent $38.0 million repurchasing its stock (net of option exercises), helping boost earnings per share (ir.corcept.com). These buybacks reflect management’s confidence in the business and provided support to the stock – at least until the recent FDA-related shocks. Given the current challenges, investors should watch whether Corcept continues repurchasing shares (taking advantage of the depressed price) or conserves cash for pipeline needs.

Financial Position and Leverage

One reassuring aspect for Corcept is its solid balance sheet. The company carries no significant debt – its financial statements show zero long-term borrowings (aside from lease liabilities) (www.sec.gov). Corcept has been able to fund operations and growth from internal cash flows, avoiding restrictive debt covenants or interest burdens. In fact, by year-end 2024, Corcept held $603.2 million in cash and investments (ir.corcept.com), reflecting the company’s strong cash generation from Korlym sales. For 2024, Corcept reported net income of $141.2 million (EPS of $1.23) (ir.corcept.com), marking its second consecutive year of profitability above $100 million. Operating cash flow for the first nine months of 2024 was $138.8 million (www.sec.gov), indicating healthy cash conversion. With no debt maturities to worry about and a cash war chest of over $600 million, Corcept is well-positioned to weather near-term challenges. Its interest coverage is a non-issue given the lack of debt interest; instead, the company can focus its financial resources on R&D, potential regulatory-required trials, and strategic investments. This strong balance sheet is a crucial buffer as Corcept navigates the fallout of relacorilant’s setback.

Valuation and Earnings Outlook

Prior to these setbacks, Corcept’s stock traded at a growth-oriented valuation, reflecting high expectations for relacorilant and expanding use of Korlym. In mid-2025, the stock reached an all-time high of around $117 per share (www.investing.com), at which point it commanded a market capitalization well above $8 billion (over 70× trailing earnings). Following the ~50% drop after the FDA rejection and the additional decline after the FDA’s letter, CORT now hovers around the high-$30s per share – roughly a $4 billion market cap. Based on 2024 results, this implies a P/E ratio in the mid-20s and an EV/Sales around ~5× (enterprise value of ~$3.5 billion versus $675M revenue). By traditional metrics, that valuation is not especially low for a one-product biotech, but it may be reasonable if Korlym can sustain growth and if any pipeline success is achieved. However, forward earnings visibility is murky. Notably, management had issued 2025 revenue guidance of $900–$950 million (ir.corcept.com) – an ambitious ~35% jump over 2024. This guidance presumably assumed continued strong uptake of Korlym in Cushing’s and possibly initial relacorilant contributions (though the PDUFA was year-end 2025). With relacorilant’s approval delayed indefinitely, investors should question whether such growth is attainable. If Korlym’s trajectory remains intact (see discussion on generics below), Corcept could still approach that range, but any slowdown or pricing pressure would make the stock appear pricier. At present, Corcept’s valuation hinges on the durability of Korlym’s cash flows and the odds of pipeline revival. A sum-of-parts view might attribute a few billion dollars to the entrenched Korlym franchise (discounted for looming competition) and the remainder to relacorilant’s now-uncertain future and other pipeline candidates. In short, CORT is no longer priced for perfection – but nor is it a clear bargain if growth stalls.

Pipeline Catalysts and Opportunities

Despite the recent failure in Cushing’s, Corcept’s pipeline still holds some potentially value-creating events in the near future. Foremost is relacorilant’s oncology program: the drug is under FDA review as a treatment for platinum-resistant ovarian cancer, with a decision (PDUFA date) scheduled around July 11, 2026 (www.biospace.com). This indication stems from Corcept’s Phase II trial of relacorilant combined with nab-paclitaxel (Abraxane) in ovarian cancer, which showed encouraging results leading to an NDA submission (filed in Sept 2025) (ir.corcept.com). An FDA approval in ovarian cancer could provide a much-needed win in mid-2026 – “a medium-term catalyst for the company, and a chance for Corcept to restore some of the value lost in its late-December sell-off” (www.spglobal.com). Moreover, Corcept has submitted a Marketing Authorization Application in Europe for relacorilant in the same ovarian cancer indication (www.biospace.com), which could expand its market if approved. Outside of relacorilant, Corcept’s pipeline features other selective cortisol modulators: for example, dazucorilant (a candidate in trials for amyotrophic lateral sclerosis, or ALS) and miricorilant (studied in metabolic and liver disorders) (ir.corcept.com). The company claims to have discovered over 1,000 proprietary cortisol-modulating compounds and is conducting clinical trials in areas ranging from solid tumors to liver disease (www.biospace.com). While these early-stage programs are not factored heavily into the stock’s valuation yet, any positive clinical updates could bolster long-term growth prospects. Finally, Corcept’s strategy to salvage relacorilant in Cushing’s bears watching. The FDA’s CRL gives the company one year to resubmit its application with additional data, or else the agency will consider the NDA withdrawn (wtaq.com). Management has stated they will meet with the FDA “as soon as possible to discuss the best path forward” (www.biospace.com). Potentially, Corcept could design a new trial or provide further analyses to address the FDA’s concerns (the CRL highlighted that the main trial failed to show a meaningful benefit over placebo and flagged serious liver injury risks in some patients (wtaq.com)). If a viable path to approval exists – for instance, targeting a narrower patient subgroup or an adjusted endpoint – it could revive relacorilant’s Cushing’s prospects down the line. However, any such solution would likely take considerable time and investment. For now, the ovarian cancer decision in mid-2026 is the key near-term catalyst that could determine whether Corcept’s narrative shifts back in a positive direction.

Risks and Red Flags

Corcept faces numerous risks that investors should keep in mind:

- Generic Competition to Korlym: Perhaps the most immediate threat is generic erosion of Corcept’s only revenue source. Teva Pharmaceuticals launched a generic version of Korlym in January 2024 after prevailing in a patent lawsuit (www.sec.gov). A U.S. court ruled on Dec 29, 2023 that Teva’s product does not infringe Corcept’s patents (ir.corcept.com) (ir.corcept.com), clearing the way for generic entry. In fact, Corcept’s stock plunged ~38% on that court decision (www.nasdaq.com). Corcept is appealing the ruling, but no injunction prevented Teva’s launch (www.sec.gov). Despite generic competition, Corcept still grew Korlym sales in 2024, implying the impact was limited initially. However, as Teva (and potentially other generics after Teva’s exclusivity) gain traction, price reductions or share loss are likely (ir.corcept.com). This could slow or reverse Corcept’s revenue growth in 2025 and beyond, undermining its high-margin cash flows. The company’s 2025 guidance acknowledged this risk, noting that increased uptake of competing medications, “including generic versions of Korlym,” could affect future revenue (ir.corcept.com). How well Corcept defends its franchise – via patient support, new formulations, or other strategies – will be critical.

- Regulatory and Pipeline Setbacks: The relacorilant CRL saga underscores the risks in Corcept’s pipeline. The FDA not only rejected the Cushing’s application but did so in unusually strong language, warning the company in advance and citing efficacy and safety issues (wtaq.com). This raises concerns about management’s judgment in pushing forward despite red flags, as well as the ultimate approvability of relacorilant for Cushing’s. There is a chance that even additional trials may not salvage the indication if the drug’s benefit is marginal or if safety (like liver toxicity) remains problematic (wtaq.com). Furthermore, upcoming pipeline events carry binary risk – for example, failure to win approval in ovarian cancer this July would remove the nearest catalyst and cast doubt on relacorilant’s usefulness in any indication. Beyond relacorilant, Corcept’s other pipeline candidates (dazucorilant, miricorilant, etc.) are at early stages and unproven. Any negative trial results or regulatory hurdles for these programs could prolong the company’s reliance on a fading Korlym.

- Management Credibility and Legal Scrutiny: The contrast between Corcept’s public optimism and the FDA’s internal warnings has drawn the attention of shareholder rights attorneys. In early January 2026, at least one law firm (Hagens Berman) launched an investigation into whether Corcept misled investors about relacorilant’s efficacy and approval prospects (www.prnewswire.com). The firm noted that investors saw shares “crater 50%” on the CRL news (www.prnewswire.com) and is probing if company statements failed to disclose the FDA’s repeated cautions. While such class-action investigations are common after biotech sell-offs, they highlight a perception issue: management’s credibility is now in question. CEO Joseph Belanoff’s comment that the company was “surprised and disappointed” by the FDA’s decision (www.biospace.com) appears at odds with the FDA’s account of multiple pre-filing warnings (www.fiercebiotech.com) (www.fiercebiotech.com). Investors will likely demand more transparency going forward. Any finding of misleading communications could lead to lawsuits or settlements, and at minimum, management faces a trust deficit. This could also impact Corcept’s relationship with regulators, which is crucial as it seeks a path forward for relacorilant and other drugs.

- Concentrated Business Risk: Corcept’s entire current revenue is derived from one product (Korlym) addressing a rare condition. This lack of diversification amplifies the impact of any single event – as seen with the generic entry and the relacorilant failure. Until Corcept either broadens its portfolio or indications, it will be particularly vulnerable to shocks. The company’s fortunes over the next few years hinge on a handful of events (e.g. an appeal decision on the Korlym patent, the ovarian cancer approval, and any new Cushing’s trial outcomes). Such concentration risk means the stock will likely remain volatile and high-risk.

Open Questions and What’s Next

With its stock down sharply and its lead growth driver derailed for now, Corcept faces several open questions as it charts the path forward:

- Can relacorilant be rescued in Cushing’s? Corcept plans to meet with the FDA to determine what additional evidence is needed (www.biospace.com). Will the company initiate a new trial (and how long might that take)? Or is the hurdle – demonstrating clear efficacy over placebo without safety issues – too high to overcome in a reasonable timeframe? Investors will be watching for any guidance from management on their regulatory strategy for relacorilant in hypercortisolism.

- How will Korlym hold up against generics? Thus far, Korlym’s growth has been robust despite Teva’s entry. But as 2025 progresses, will we start to see an impact on sales or pricing? Management’s commentary on Cushing’s market trends (e.g. patient adds, any need for price cuts or higher rebates) will be key. The outcome of Corcept’s appeal of the patent case is another wildcard – a reversal in late 2025 or 2026 (after the July appellate hearing (www.sec.gov)) could potentially reinstate some patent protection, but few analysts appear to be banking on that outcome.

- What will July 2026 bring? The FDA decision on relacorilant in ovarian cancer is pivotal. Approval could open a new revenue stream and validate Corcept’s cortisol modulation approach in oncology, while rejection would deal another blow to the pipeline. Even if approved, questions remain about the market size and adoption in platinum-resistant ovarian cancer – a challenging setting with competing treatments. How significant would relacorilant’s commercial opportunity be in oncology, and could that use-case compensate for the Cushing’s setback?

- Does Corcept need to pivot or partner? Given the company’s cash-rich status and single-product focus, will Corcept consider strategic moves to diversify? This could include licensing or acquiring complementary assets in endocrinology or adjacent fields to reduce reliance on Korlym. Alternatively, Corcept itself could become a takeout candidate for a larger pharma looking for a rare-disease revenue stream (though the presence of a generic may dissuade would-be acquirers). Any indications from management about business development, partnerships, or changes in R&D prioritization will be important to gauge the company’s next steps.

In summary, Corcept Therapeutics is at a crossroads. The FDA’s tough stance on relacorilant has once again knocked the stock down, forcing a reassessment of the company’s growth narrative. On the positive side, Corcept’s underlying Cushing’s business remains sizable and profitable, fueling a strong balance sheet that provides time to regroup. The company’s expertise in cortisol biology and diverse pipeline could still yield future successes – the upcoming ovarian cancer decision is one such opportunity (www.spglobal.com). On the negative side, the twin challenges of an immediate generic threat and a delayed flagship drug create a difficult road ahead. Investors will need to see evidence that Corcept can adapt its strategy – whether by extracting more value from Korlym (e.g. new formulations or expanded use), successfully bringing new therapies to market, or improving transparency and execution with regulators. Until those questions are resolved, CORT will likely remain a “show me” story, trading more on clinical and legal outcomes than on fundamentals. The next 6–12 months – with regulatory meetings, a critical FDA decision, and the evolution of Korlym’s competitive landscape – should provide a clearer picture of whether Corcept can get back on a growth trajectory or if further challenges lie ahead. Investors in CORT should be prepared for ongoing volatility, but also stay alert for positive surprises that could emerge as the company works to unlock value from its pipeline and expertise in cortisol modulation.

Sources: The analysis above is grounded in information from official company filings and releases, as well as reputable financial media. Key references include Corcept’s 2024 earnings report and FDA CRL press release (ir.corcept.com) (www.biospace.com), the FDA’s complete response letter details reported by Reuters (wtaq.com), industry coverage by S&P Global Market Intelligence (www.spglobal.com) (www.spglobal.com), and other newswire reports (AP, Bloomberg, Nasdaq/Zacks) regarding the patent litigation and share price moves (www.nasdaq.com) (www.prnewswire.com). These sources provide a factual basis for evaluating Corcept’s recent setbacks, financial health, and future outlook.